Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: Demonstration of a central effect for the 5HT(1B/1D) agonist zolmitriptan (311C90, Zomig®)

Cephalalgia

Volumn 17, Issue 8, 1997, Pages 849-854

  Proietti Cecchini, A ^a   Afra J ^a   Schoenen, J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

5HT(1B D) receptors; Cortical auditory evoked potential; Migraine; Serotonin; Zolmitriptan

Indexed keywords

ANTIMIGRAINE AGENT; DEXFENFLURAMINE; LORAZEPAM; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EVOKED AUDITORY RESPONSE; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ADULT; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; SEROTONIN AGONISTS; SYNAPTIC TRANSMISSION; TRYPTAMINES;

EID: 0031452152     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1708849.x     Document Type: Article

References (25)

1. Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995;2:5-21
2. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-6
3. Kaube H, Hoskin KL, Goadsby PJ. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-92
4. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90. Headache 1994;34:394-9
5. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT)-1D agonist Zolmitriptan (311C90): Are brain stem sites a therapeutic target in migraine? Pain 1996;67:355-9
6. Hoskin KL, Kaube H, Coadsby PJ. Central activation of trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996;119:249-56
7. 3H]sumatriptan-binding sites in post-mortem human brain. Cephalalgia 1996;16:317-22
8. Schoenen J, Klein KB, Sweet RM for the Multinational Oral 311C and Sumatriptan Comparative Study Group. The CNS adverse event profiles of 311C90 and sumatriptan appear identical. Eur J Neurol 1996;3 Suppl 5:153
9. Göbel H, Krapat S, Dworschak M, Heuss D, Ensink FBM, Soyka D. Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan. Cephalalgia 1994;14:143-8
10. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, et al. A multinational, double-blind, placebo-controlled, dose range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995;35:292
11. Martin GR. Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selective targeting additional sites of action. Eur Neurol 1996;36 Suppl 2:13-18
12. Schoenen J, Caekebeke P, Louis G, Monseu G, Phillips S, Pierre P. An open study to investigate the absorption and tolerability of oral 311C90 and to obtain a preliminary indication of an efficacy in migraine patients. In: Clifford Rose F, editor. Proceedings of the 10th Migraine Trust Symposium, New Advances in Headache Research 4. London: Smith-Gordon, 1994:11-12
13. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of serotonergic neurotransmission: a new hypothesis. Biol Psychiatr 1993;33:173-87
14. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996;46:1404-9
15. Buchsbaum MS, Gillin JC, Pfefferbaum A. Effect of sleep stage and stimulus intensity on auditory average evoked responses. Psychophysiology 1975;12:707-12
16. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurology 1996; 46:522-6
17. Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 1990;29:511-13
18. 3H]5-HT release in raphe, frontal cortex and hippocampus of 5-HT1B knock-out mice. NeuroReport 1995;7:353-9
19. Mitsikostas DD, Papadopoulou-Daifotis Z, Sifkakis A, Varanos D. The effect of sumatriptan on brain monoamines in rats. Headache 1996;36:29-31
20. Schoenen J, Raubüschl O, Sianard J. Pharmacologic modulation of temporalis exteroceptive silent periods in healthy volunteers. Cephalalgia 1991;11 Suppl 11:16-17
21. Mason P. Intracellular responses of raphe magnus neurons during the jaw-opening reflex evoked by tooth pulp stimulation. Brain Res 1986;379:232-41
22. Göbel H, Krapat S, Ensink FBM, Soyka D. Comparison of contingent negative variation between migraine interval and migraine attack before and after treatment with sumatriptan. Headache 1993;33:570-2
23. Ferrari MD, Odink J, Tapparelli C, Van Kempen CM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology 1989;39:1239-42
24. 2+ channel gene CACNL1A4. Cell 1996;87:543-52
25. Sicuteri F, Anselmi B, Del Bianco PL. Dopamine and 5-HT supersensitivity in non-organic central pain and in morphine abstinence: fortuitous or renal analogy? Adv Biochem Psychopharmacol 1980;22:523-33